NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

NUWE

Nuwellis Inc

Apr 17 • 04:00PM ET

0.9345

Dollar change +0.0425
Percentage change 4.76	%

Healthcare • Medical Devices • USA • NASD

Peers: BAX ICUI GMED CNMD EW PEN OFIX IART ZYXI ATEC

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-38.64	Insider Own	0.00%	Shs Outstand	4.37M	Perf Week	-0.37%
Market Cap	4.09M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-	Shs Float	4.37M	Perf Month	-16.56%
Income	-10.62M	PEG	-	EPS next Q	-0.45	Inst Own	1.89%	Short Float	3.80%	Perf Quarter	-13.87%
Sales	8.74M	P/S	0.47	EPS this Y	83.47%	Inst Trans	124.09%	Short Ratio	0.39	Perf Half Y	-35.55%
Book/sh	1.49	P/B	0.63	EPS next Y	62.59%	ROA	-113.73%	Short Interest	0.17M	Perf Year	-92.03%
Cash/sh	1.16	P/C	0.80	EPS next 5Y	-	ROE	-229.24%	52W Range	0.75 - 14.00	Perf YTD	-15.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	90.39%	ROI	-155.39%	52W High	-93.33%	Beta	0.48
Dividend TTM	-	Quick Ratio	2.79	Sales past 5Y	10.34%	Gross Margin	64.94%	52W Low	24.50%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	3.46	EPS Y/Y TTM	91.79%	Oper. Margin	-125.72%	RSI (14)	45.19	Volatility	6.45% 9.79%
Employees	38	Debt/Eq	0.08	Sales Y/Y TTM	-1.40%	Profit Margin	-121.56%	Recom	1.00	Target Price	13.00
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	99.44%	Payout	-	Rel Volume	0.09	Prev Close	0.89
Sales Surprise	-5.67%	EPS Surprise	-2.33%	Sales Q/Q	-8.98%	Earnings	Mar 11 BMO	Avg Volume	430.26K	Price	0.93
SMA20	-1.18%	SMA50	-16.75%	SMA200	-42.37%	Trades		Volume	40,030	Change	4.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-24	Initiated	ROTH MKM	Buy	$17

Mar-11-25 08:00AM	Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 04:05PM	Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO (GlobeNewswire) -5.56%
Feb-20-25 08:00AM	JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis (GlobeNewswire) -6.85%
Feb-18-25 04:15PM	Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025 (GlobeNewswire) +11.45%
Jan-13-25 08:00AM	Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow Therapy (GlobeNewswire)
09:00AM	Loading…
Dec-19-24 09:00AM	Nuwellis Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-11-24 08:00AM	Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) +13.26%
Nov-05-24 09:28AM	Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds (GlobeNewswire) -34.52%
Nov-04-24 01:43PM	Nuwellis Stock Soars 121% on Major Increase in Reimbursement for Aquadex System (GuruFocus.com) +106.62%
08:30AM	Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow Therapy from the Centers for Medicare and Medicaid (GlobeNewswire)
Nov-01-24 04:15PM	Nuwellis Announces Preliminary Results for Third Quarter of 2024 (GlobeNewswire) -20.93%
Oct-31-24 08:00AM	Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer (GlobeNewswire) -11.79%
Oct-23-24 04:15PM	Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024 (GlobeNewswire) -26.27% -5.75%
Sep-25-24 04:15PM	Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Aug-27-24 09:00AM	New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy (GlobeNewswire)
09:00AM	Loading…
Aug-23-24 09:00AM	Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -26.16%
Aug-13-24 08:00AM	Nuwellis, Inc. Announces Second Quarter 2024 Financial Results (GlobeNewswire) -19.25%
Aug-08-24 09:00AM	Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions (GlobeNewswire)
Jul-26-24 09:00AM	Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE Therapy at Cincinnati Children's (GlobeNewswire)
Jul-24-24 08:02AM	Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -40.00%
Jul-23-24 04:10PM	Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire) +8.36%
Jul-17-24 09:00AM	Nuwellis Marks First Commercial Sale of QUELIMMUNE Therapy to Cincinnati Children's (GlobeNewswire) -6.77%
Jul-12-24 08:30AM	SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner (GlobeNewswire) +8.70%
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-09-24 09:00AM	New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference (GlobeNewswire)
Jun-26-24 08:45AM	Nuwellis Announces Reverse Stock Split (GlobeNewswire) -34.25%
Jun-25-24 09:00AM	Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian (GlobeNewswire)
Jun-06-24 09:00AM	Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase (GlobeNewswire)
May-14-24 09:00AM	Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida (GlobeNewswire) -7.17%
May-09-24 09:00AM	Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy (GlobeNewswire) +5.58%
12:53PM	Loading…
May-07-24 12:53PM	NUWE Stock Earnings: Nuwellis Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +54.04%
08:00AM	Nuwellis, Inc. Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 09:00AM	Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology (GlobeNewswire) +54.89%
Apr-30-24 06:09PM	Nuwellis Announces Closing of $2.7 Million Public Offering (GlobeNewswire) +7.22% -13.86%
04:41PM	Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-26-24 09:17AM	Nuwellis Announces Pricing of $2.7 Million Public Offering (GlobeNewswire) -41.94%
Apr-09-24 09:00AM	Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow System at Henry Ford Health (GlobeNewswire)
Mar-07-24 09:08AM	Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Mar-05-24 08:00AM	Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -16.76%
Feb-27-24 09:00AM	Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (GlobeNewswire) -11.26%
Feb-22-24 07:58AM	Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune (GlobeNewswire)
Feb-20-24 05:06PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.41% -11.25%
08:42AM	Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Feb-06-24 09:00AM	New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload (GlobeNewswire) -7.29%
Jan-04-24 03:05PM	Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter (GlobeNewswire) -14.64%
Nov-28-23 08:00AM	New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients (GlobeNewswire)
Nov-14-23 04:30PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-23 01:08PM	Nuwellis, Inc. (NASDAQ:NUWE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:00AM	Nuwellis, Inc. Announces Third Quarter 2023 Financial Results (GlobeNewswire) -5.54%
Nov-01-23 08:00AM	Nuwellis Announces Board of Directors Transition (GlobeNewswire) -5.50%
Oct-31-23 08:00AM	Nuwellis' Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device (GlobeNewswire) -8.95%
Oct-18-23 04:15PM	Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) +8.18%
Oct-17-23 04:15PM	Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants (GlobeNewswire) -5.77%
Oct-13-23 08:30AM	Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants (GlobeNewswire) -9.40%
Oct-10-23 08:00AM	Nuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption (GlobeNewswire) -16.94%
Sep-11-23 04:15PM	Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase (GlobeNewswire) -12.50%
Aug-08-23 08:15AM	Nuwellis, Inc. Announces Second Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Nuwellis Announces Plan for CFO Transition (GlobeNewswire)
Jul-18-23 04:15PM	Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jun-20-23 08:30AM	Nuwellis Inc. Announces Pilot Agreement With DaVita Inc. (GlobeNewswire)
Jun-13-23 04:15PM	Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire) +7.27%
Jun-05-23 04:15PM	Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors (GlobeNewswire)
May-22-23 05:10PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-09-23 08:00AM	Nuwellis, Inc. Announces First Quarter 2023 Financial Results (GlobeNewswire) -27.87%
Apr-18-23 08:00AM	Nuwellis, Inc. To Announce First Quarter 2023 Financial Results on May 9, 2023 (GlobeNewswire)
Mar-21-23 08:00AM	Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics (GlobeNewswire)
Mar-01-23 08:00AM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-23 08:00AM	Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -6.05%
Feb-23-23 04:15PM	Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire) +16.15%
08:00AM	Clinical Data Supports the Role of Ultrafiltration in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) (GlobeNewswire)
Feb-07-23 08:00AM	Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023 (GlobeNewswire)
Jan-09-23 08:00AM	Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results (GlobeNewswire) +11.48%
Jan-05-23 02:40PM	Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer (GlobeNewswire) -25.48%
Jan-04-23 05:25PM	Nuwellis, Inc. Announces Passage of Warrant Proposal (GlobeNewswire)
Dec-29-22 01:35PM	SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medicals Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI) (GlobeNewswire) +32.17%
Dec-27-22 04:45PM	Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements (GlobeNewswire) -12.24% +37.48%
Dec-13-22 08:00AM	Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex (GlobeNewswire)
Dec-08-22 08:10AM	Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Nov-30-22 08:00AM	Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -8.27%
Nov-18-22 05:00PM	Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.14% -8.00%
Nov-08-22 08:00AM	Nuwellis, Inc. Reports Third Quarter 2022 Financial Results (GlobeNewswire) -12.21%
Nov-03-22 07:00AM	Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates (GlobeNewswire)
Oct-19-22 04:15PM	Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) -6.09%
07:00AM	Nuwellis Announces Appointment of Chief Financial Officer (GlobeNewswire)
Oct-18-22 04:15PM	Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option (GlobeNewswire) -7.60%
Oct-14-22 08:30AM	Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering (GlobeNewswire) -21.54%
Oct-03-22 07:00AM	Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting (GlobeNewswire) -22.10%
Sep-27-22 07:00AM	Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial (GlobeNewswire)
Aug-31-22 07:00AM	Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients (GlobeNewswire) +131.71%
Aug-25-22 07:00AM	U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology (GlobeNewswire) +7.92%
Aug-19-22 03:00PM	Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Nuwellis Inc. to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase (GlobeNewswire)
Aug-09-22 08:00AM	Nuwellis, Inc. Announces Second Quarter 2022 Financial Results (GlobeNewswire) -8.62%
Jul-26-22 07:00AM	Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA (GlobeNewswire)
Jul-14-22 08:00AM	Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022 (GlobeNewswire)
Jul-12-22 07:00AM	Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy (GlobeNewswire)
Jun-29-22 07:00AM	Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF (GlobeNewswire) +9.91%
Jun-14-22 07:00AM	Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas (GlobeNewswire)
May-17-22 04:25PM	Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) -5.64%
May-10-22 08:00AM	Nuwellis, Inc. Announces First Quarter 2022 Financial Results (GlobeNewswire)

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NUWE

Nuwellis Inc

Upgrade your FINVIZ experience